Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

(2022) Nicolas Margot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

(2022) Sorana Segal-Maurer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

(2021) Hadas Dvory-Sobol et al.   Current Opinion in HIV and AIDS

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes

(2020) Nicolas Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

(2020) Edgar T Overton et al.   LANCET

HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors

(2015) Paul Spearman   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa

(2009) Stephen D Lawn et al.   AIDS